" />
Skip to main content
Navigate Up
Sign In

Mucosal and Vaccine Research Colorado

Funding Options




the Two 2010 $20,000 MAVRC Pilot Award Winners!  


"Ribonuclease L, RIG-I, Interferon and Immunity to Hepatitis C Virus"


David J. Barton, PhD   David J. Barton, Ph.D.  (See BIO)

University of Colorado School of Medicine

Associate Professor of Microbiology


Phone: (303) 724-4215



Hugo Rosen, M.D.

Hugo Rosen, M.D.  (See BIO)

University of Colorado School of Medicine

Waterman Professor of Medicine and Immunology

Head, Division of Gastroenterology & Hepatology


Phone: (303) 724-1858



Jay Hesselberth, Ph.D.  Jay R. Hesselberth, Ph.D.  (See BIO)

University of Colorado School of Medicine

Assistant Professor, BioChemistry and Molecular Genetics


Phone: (303) 724-5384



The Barton, Hesselberth and Rosen labs are working collaboratively to develop new methods that will detect and quantify the antiviral activity of ribonuclease L (RNase L) in liver biopsies from hepatitis C virus (HCV)-infected patients.


Interferon is commonly used to treat patients infected with HCV. Some strains of HCV are more resistant to interferon therapy than others; however, the molecular basis for interferon sensitivity and resistance in patients remains largely unexplained. RNase L, an antiviral host enzyme produced in interferon-treated cells, is predicted to inhibit HCV replication and to affect the outcomes of interferon therapy; however, no one has evidence to establish whether RNase L inhibits HCV in the liver of patients.


The Barton lab and collaborators have used biochemical experiments, tissue culture studies, animal models and bioinformatic approaches to characterize the antiviral activity of RNase L as it relates to HCV infections. The goal of the current project funded by MAVRC is to use liver biopsies from HCV-infected patients to test whether RNase L cleaves HCV RNA naturally in the liver of patients, as predicted.


 "Phenotyping the spectrum of latent tuberculosis infection through host expression profiling: The Expression in Pneumonia and Tuberculosis (ePAT) study"


 Randall Reves, M.D.         Randall R. Reves, M.D./M.Sc.  (See BIO at Denver Health)

Denver Health Medical Center

Professor, Infectious Diseases


Phone: (303) 602-7257 


Nicholas Walter, MD


 Nicholas Walter, M.D., M.S. 

University of Colorado Denver

Fellow, Pulmonary Sciences and Critical Care Medicine 


Phone: (303) 724-4075


Michael Strong, PhD  Michael Strong, Ph.D.  (See BIO)

National Jewish Health, Denver

Assistant Professor, Center for Genes, Environment and Health


Phone: (303) 270-2782



Charles Daley, MD


 Charles Daley, M.D.  (See BIO)

National Jewish Health, Denver

Chief, Mycobacterial and Respiratory Infections


Phone: (303) 398-1667


Mark Geraci, MD


 Mark Geraci, M.D.  (See BIO)

University of Colorado Denver

Professor of Medicine, Pulmonary Sciences and Critical Care Medicine  


Phone: (303) 724-6040



Tuberculosis (TB) is an on-going public health crisis, causing 1.6 million deaths worldwide each year. It is estimated that approximately one-third of the world's population has latent TB infection (LTBI). However, even without treatment, fewer than 10% of latently infected immunocompetent persons develop TB over the course of a lifetime. Identifying the persons with LTBI who are most likely to progress to TB is a key public health priority but currently available tests for LTBI cannot risk-stratify among patients with latent infection.

Expression profiling -- the analysis of patterns of RNA expression in human clinical samples -- is a novel and potentially powerful means of identifying the subgroup of persons with LTBI who are at highest risk for developing TB. Whole-genome micro-array quantifies an individual's expression of approximately 28,000 RNA transcripts, providing a "biological snapshot" of ongoing transcriptional adaptation to physiologic stressors. We seek to identify host expression profiles in peripheral blood that distinguish patients with TB and LTBI from well controls and from patients with non-TB pneumonia.

ePAT is a longitudinal study of host gene expression among patients at Denver Health Medical Center with TB, LTBI, community acquired pneumonia and no infection.  Through a new collaboration among investigators at Denver Health, National Jewish Health and the University of Colorado Denver, we aim to identify TB and LTBI-specific host expression profiles and to characterize the change in these profiles during the course of therapy.   


The 2009 MAVRC Pilot Fund Awardees for Human Immunobiology Studies. Congratulations to the recipients of the two $25,000 awards for innovative and collaborative research projects to explore mucosal and vaccine biology. 

 Photo-Dr. Adit Ginde

     Dr. Adit Ginde


Vitamin D Supplementation and Varicella Zoster Virus Vaccine Responsiveness in Older Nursing Home Residents

PI:     Adit A. Ginde, MD, MPH; Assistant Professor of Surgery

Co-I:  Myron J. Levin, MD; Professor of Pediatrics

Co-I:  Robert S. Schwartz, MD; Professor of Medicine


J. David Beckham, MD - Photo

Dr. David Beckham


Cytokine Biomarkers in Patients with Central Nervous System Infections

PI:     David Beckham, MD; Assistant Professor of Infectious Diseases

Co-I:  Kenneth L. Tyler, MD; Professor of Neurology, Infectious

               Diseases, and Microbiology

Co-I:  Charles A. Dinarello, MD; Professor of Infectious Diseases


        American Society for Microbiology/Coordinating Center for Infectious Diseases

        amfAR (The Foundation for AIDS Research)

        Association Francois Aupetit

        • A patient association funding research on Crohn's dis

        Bill & Melinda Gates Foundation

        Biotechnology and Biological Sciences Research Council (BBSRC)

        Boettcher Foundation

        Broad Medical Research Program

        Burroughs Wellcome Fund

        Butcher Symposium of Genetics and Biotechnology

        Canadian Institutes of Health Research

        Caring for Colorado Foundation

        Centers for AIDS Research (CFAR)

        Center for Global Health

        Colorado Bioscience Research Grant

        Colorado Clinical & Translational Sciences Institute (CCTSI)

        Colorado Department of Public Health and Environment (CDPHE)

        Crohn's & Colitis Foundation of America

        Crohn's & Colitis Foundation of Canada

        Deutsche Gesellschaft für Verdauungs - und Stoffwechselkrankheiten
        (German society of digestive and metabolic diseases)

        Elizabeth Glaser Pediatric AIDS Foundation

        Human Frontier Science Program

        Institut National de la Sante et de la Recherche (INSERM)

        James S. McDonnell Foundation

        Juvenile Diabetes Research Foundation

        March of Dimes Colorado

        Medical Research Council

        Medimmune Grants

        Mizutani Foundation for Glycoscience

        Mountains & Plains Education and Research Center

        National Institutes of Health (NIH)

        National Science Foundation

        Office of Research Development and Education (ORDE)

        Pfizer Funding Opportunities

        Sarnoff Cardiovascular Research Foundation

        Seventh Framework Programme-Marie Curie Actions

        University of Colorado Denver - School of Medicine

        The Colorado Health Foundation

        The Stanley Medical Research Institute (SMRI)

        The Wellcome Trust

        Thrasher Research Fund

        University of Colorado Cancer Center


          Mucosal and Vaccine Research Colorado

          12631 East 17th Avenue, Suite 7408 • Mail Stop 8205 • Aurora, CO 80045

        Program Administrator:  Carola Hagenau  Phone: 303-724-8499 • Fax: 303-724-0802 • E-mail: MAVRC@ucdenver.edu                           

          http://ucdenver.edu/MAVRC • DirectionsVisitor Parking Map                              Executive Director: Edward N. Janoff, MD   


        © The Regents of the University of Colorado, a body corporate. All rights reserved.

        Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.